الفهرس 
The role of Erythropoietin in Acute Kidney injuryOnly 14 pages are availabe for public view
 |  | from | 62 |  |  |
| | | from | 62 | | |
Abstract
Erythropoietin (EPO) is the principal hematopoietic hormone produced by the kidney and the liver in fetuses, regulates mammalian erythropoiesis. rHuEPO may also have additional therapeutic effects in vivo, such as recruitment of vascular progenitor cells that may promote tissue repair following various stresses
Production and secretion of EPO and EPOR expression are regulated by the tissue oxygen supply, via the hypoxia-inducible factor 1 (HIF-1), EPO has essentially eliminated severe anemia as a major cause of morbidity in dialysis patients.EPO treatment is generally recommended for use in hemodialysis patients who have a hemoglobin level of less than 10 g/dL, uses of ESAs raises Hb levels and reduces the frequency of red blood cell transfusions in anemic cancer patients who are receiving chemotherapy
rHuEPO therapy enhances cardiac output, reduces sympathetic tone, increases peripheral vascular resistance, improves coronary circulation and exercise tolerance, induces regression of LVH and increases LVEF in patients with LV dysfunction. Apoptotic cell death of cardiomyocytes was prevented by co- and pre-treatment with recombinant EPO, soEPO administration reduces the myocardial infarct size after ischemia. rHuEPO administration along with intravenous iron to patients with CHF improved NYHA functional class, EF, the number of hospitalized days, the dose of diuretics and slowed the rate of progression of renal failure.
Application of systemic rHuEPO following subarachnoid hemorrhage restores the autoregulation of cerebral blood flow, reverses basilar artery vasoconstriction, and enhances neuronal survival and functional recovery, Systemic administration of EPO also reduced the infarct size,
EPO administration protects kidney tissue from damage and improves renal function in ischemia-reperfusion (IR) and contrast-induced injury of AKI, in which EPO reduced kidney dysfunction by decreasing apoptosis.